Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2025-08-22 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
2025年半年度募集资金存放及实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2025 Half-Year Special Report on the Deposit and Actual Use of Raised Funds" by a pharmaceutical company. It details the use and management of funds raised through an initial public offering, including amounts raised, usage, balances, and compliance with regulatory requirements. The document references specific regulatory rules related to fundraising and fund management, and provides detailed financial data on the use of these funds for investment projects and cash management. The content is focused on the management and use of capital raised, rather than general financial performance or earnings. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is over 5,000 characters and contains substantive financial data, so it is not a mere announcement or certification. Therefore, the appropriate classification is CAP.
2025-08-22 Chinese
关于筹划公司在香港联合交易所有限公司上市的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (701 characters) regarding the company's plan to list its shares on the Hong Kong Stock Exchange. It discusses the intention to issue overseas shares (H shares) and the regulatory approvals required. There is no detailed financial data, no full report, and no mention of actual financial results or comprehensive disclosures. The document serves as a notification of a planned capital market action rather than the action itself or a detailed report. According to the rules, such short announcements about upcoming filings or plans are classified as Regulatory Filings (RNS) because they do not contain substantive financial or operational data and are not formal filings like prospectuses or capital change announcements yet.
2025-08-22 Chinese
2025年上半年提质增效重回报专项行动方案的半年度评估报告
Interim / Quarterly Report Classification · 95% confidence The document is a half-year assessment report on the implementation of a special action plan for 2025 by the company 科兴生物制药股份有限公司. It contains detailed operational and financial performance data for the first half of 2025, including revenue, net profit, business strategy, R&D progress, overseas market expansion, shareholder returns, and governance improvements. The presence of actual financial figures and comprehensive management discussion indicates this is a substantive interim report rather than a brief announcement or certification. The document length is 4672 characters, which is sufficient for a detailed interim report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-22 Chinese
第二届监事会第二十五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of the company regarding the approval of the 2025 half-year (semi-annual) report and a special report on the use of raised funds. It states that the half-year report and related documents have been disclosed on the stock exchange website, indicating this document is an announcement of the meeting resolution rather than the report itself. The document length is short (1026 characters) and it references the actual half-year report being published elsewhere. According to the rules, such a document is classified as a Regulatory Filing (RNS) because it is an announcement related to the report but does not contain the substantive financial data or the report itself.
2025-08-22 Chinese
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "科兴生物制药股份有限公司2025 年半年度报告" which translates to "Kexing Biopharmaceutical Co., Ltd. 2025 Semi-Annual Report." It contains detailed financial data, management discussion and analysis, company overview, risk factors, and other comprehensive information typical of a semi-annual or interim financial report. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. It explicitly states it is a half-year report (半年度报告) and includes financial statements and management commentary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-22 Chinese
2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2025 半年度报告摘要' which translates to '2025 Semi-Annual Report Summary'. It contains detailed financial data such as total assets, net profit, earnings per share, and shareholder information for the half-year period. The document explicitly states it is a summary of the half-year report and references the full half-year report for more details. The length is 3026 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. The content includes management discussion and analysis references, financial metrics, and shareholder data typical of an Interim / Quarterly Report. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-22 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.